Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ascletis Pharma, Inc. ( (HK:1672) ) has provided an announcement.
Ascletis Pharma Inc. announced that it will present the results of its 28-day multiple ascending dose study of ASC30, an oral small molecule GLP-1 receptor agonist, at the European Association for the Study of Diabetes Annual Meeting in Vienna. The study demonstrated superior weight loss in participants with obesity, positioning ASC30 as a potentially differentiated treatment option. The company is on track to report topline data from a Phase IIa clinical study in the fourth quarter of 2025, which could enhance its market position in obesity treatment.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative drugs for the treatment of liver diseases, viral infections, and cancer. The company specializes in oral small molecule drugs and has a strong emphasis on research and development to address unmet medical needs.
Average Trading Volume: 8,349,148
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.66B
For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.